viewReNeuron Group PLC

ReNeuron raising up to £15mln to fund two key R&D programmes

The new investment that will be used to fund an expanded study on its treatment for a degenerative eye disease and to deliver proof-of-concept data from its exosome collaborations

ReNeuron Group PLC -

ReNeuron Group PLC (LON:RENE) is raising up to £15mln, which will be invested in an expanded study on its treatment for a degenerative eye disease and to deliver proof-of-concept data from its exosome collaborations.

The new money will come in two tranches: A £13.9mln placing at 70p a share and a subscription offer of up to £1.1mln. The fundraiser extends the company’s cash runway by a further 18 months.

ReNeuron said it plans to expand its phase IIa study in the US and UK treating people with the genetic eye disorder retinitis pigmentosa using its hRPC cell therapy candidate. To date, the signs of efficacy have been “encouraging”, it added.

Some of the proceeds will also be deployed to assess the potential of ‘cellular couriers’ called exosomes to deliver therapeutic agents to the brain.

ReNeuron currently has three collaboration agreements with unnamed major pharmaceutical and biotechnology companies.

It expects to generate pre-clinical proof-of-concept results in the first half of next year.

In a separate statement, the research and development group announced interim results, which showed costs fell by £3.9mln to £7.9mln as it narrowed its remit to focus on its retinitis pigmentosa and exosomes programmes. The loss for the six months to September 30, 2020, was £7.1mln.

Cash used during the period fell to £2.6mln from £5.8mln and it exited the half with £9.8mln in the bank.

"Our decision earlier this year to focus the company's resources on our retinal disease programme and our exosome and iPSC platforms has resulted in significantly lower operating costs, as reflected in the interim results for the period under review,” said chief executive Olav Hellebø in the results statement.

“This renewed clarity of focus, together with the fundraise announced separately yesterday, will enable us to reach important, data-driven value inflexion points across our programmes over the next 12 months and beyond."

Quick facts: ReNeuron Group PLC

Price: 133.9875 GBX

Market: LSE
Market Cap: £73.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...


Market Report: Biden reveals $1.9tn coronavirus stimulus package

FTSE 100 continued its recent seesaw with disappointment over US stimulus measures and concern over new coronavirus strains sending London lower Again. The blue-chip index dropped 44 to 6,757. Investors reacted coolly to US President-elect Joe Biden’s keenly anticipated US$1.9tn (£1.4tn)...

3 days, 6 hours ago

2 min read